Ulipristal

Brand names: Ella · Active ingredient: Ulipristal Acetate

In short: Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure . Ella is not intended for routine use as a contraceptive.

Forms & strengthsThe ella tablet is supplied as a white to off-white, round, curved tablet containing 30 mg of ulipristal acetate and is marked "ella" on both sides.
LabelPMI Branded Pharmaceuticals, Inc.
Label updatedJul 24, 2026

What is Ulipristal used for?

Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure . Ella is not intended for routine use as a contraceptive.

Ulipristal dosage

•Take one tablet of ella orally as soon as possible within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure.

•Take ella with or without food.

•Take ella at any time during the menstrual cycle.

After ella use, initiate or resume hormonal contraception no sooner than 5 days after the intake of ella and use a reliable barrier method until the next menstrual period. For known or suspected failure of hormonal contraception refer to the hormonal contraceptive’s prescribing information for instructions on what to do .

If vomiting occurs within 3 hours of taking ella, consider repeating the dose.

How to take Ulipristal — instructions & advice from the label

Advise the patient to read the FDA-Approved patient Labeling (Patient Information).

Administration Instructions

•Instruct patients to take ella as soon as possible and not more than 120 hours after unprotected intercourse or a known or suspected contraceptive failure.

•Advise patients to contact their healthcare provider immediately in case of vomiting within 3 hours of taking the tablet, to discuss whether to take another tablet.

•Advise patients that after using ella, a reliable barrier method of contraception should be used for all subsequent acts of intercourse until the next menstrual period.

•Advise patients that after using ella, additional levonorgestrel emergency contraceptive pills should not be used within 5 days of ella intake.

•Advise patients that after using ella, hormonal contraception should be initiated or resumed no sooner than 5 days after the intake of ella and to use a reliable contraceptive barrier method until the next menstrual period.

•Advise patients with known or suspected failure of a hormonal contraceptive to refer to the hormonal contraceptive’s prescribing information for instructions on what to do. …

Warnings & precautions

Do not take this medicine if: Ella is contraindicated for use in the case of known or suspected pregnancy .

Ella is not indicated for termination of an existing pregnancy.

A history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. Healthcare providers, however, should consider the possibility of ectopic pregnancy in women who become pregnant or complain of lower abdominal pain after taking ella. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking ella.

Ella is for occasional use as an emergency contraceptive. It should not replace a regular method of contraception. Repeated use of ella within the same menstrual cycle is not recommended, as safety and efficacy of repeat use within the same cycle has not been evaluated.

A CYP3A4 inducer, rifampin, decreases the plasma concentration of ella significantly. Ella should not be administered with CYP3A4 inducers .

A rapid return of fertility is likely following treatment with ella for emergency contraception.

After use of ella, a reliable barrier method of contraception should be used with subsequent acts of intercourse until the next menstrual period.

After using ella, if a woman wishes to initiate hormonal contraception as a regular method, she can do so, no sooner than 5 days after the intake of ella and she should use a reliable barrier method until the next menstrual period [see Dosage and Administration (2.2), Drug Interactions (7.1 and 7.3) and Clinical Pharmacology (12.2)

].

Progestin-containing contraceptives may impair the ability of ella to delay ovulation. Advise women to follow the instructions on the initiation or resumption of hormonal contraceptives after ella intake .

After ella intake, menses sometimes occur earlier or later than expected by a few days. …

Ulipristal side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Ella was studied in an open-label multicenter trial (Open-Label Study) and in a comparative, randomized, single-blind, multicenter trial (Single-Blind Comparative Study). In these studies, a total of 2,637 (1,533 + 1,104) women in the 30 mg ulipristal acetate groups were included in the safety analysis. The mean age of women who received ulipristal acetate was 24.5 years and the mean body mass index (BMI) was 25.3. The racial demographics of those enrolled were 67% Caucasian, 20% Black or African American, 2% Asian, and 12% other.

The most common adverse reactions (≥ 10%) in the clinical trials for women receiving ella were headache (18% overall), nausea (12% overall) and abdominal and upper abdominal pain (12% overall). Table 1 lists those adverse reactions that were reported in ≥ 5% of subjects in the clinical studies (14). …

Drug interactions

Several in vivo drug interaction studies have shown that ella is predominantly metabolized by CYP3A4.

CYP3A inducers

Drugs or herbal products that induce CYP3A4 decrease the plasma concentrations of ella, and may decrease its effectiveness . Avoid co-administration of ella and drugs or herbal products such as:

•barbiturates

•bosentan

•carbamazepine

•felbamate

•griseofulvin

•oxcarbazepine

•phenytoin

•rifampin

•St. John's Wort

•topiramate

Hormonal contraceptives

Progestin-containing contraceptives may impair the ability of ella to delay ovulation. After using ella, if a woman wishes to initiate or resume hormonal contraception, she can do so, no sooner than 5 days after the intake of ella and she should use a reliable barrier method until the next menstrual period. If a woman used ella due to a known or suspected failure of her hormonal contraception refer to the hormonal contraceptive’s prescribing information for instructions on what to do [see Dosage and Administration (2.2), Warnings and Precautions (5.5) and Clinical Pharmacology (12.2)].

CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of ella

.

Hormonal contraceptives: ella may impact the effect of the progestin component of hormonal contraceptives. …

About this medicine

The ella (ulipristal acetate) tablet for oral use contains 30 mg of a single active steroid ingredient, ulipristal acetate [17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione], a synthetic progesterone agonist/antagonist. The inactive ingredients are lactose monohydrate, povidone K-30, croscarmellose sodium and magnesium stearate.

Ulipristal acetate is a white to yellow crystalline powder which has a molecular weight of 475.6. The structural formula is:

C30H37NO4

How it works: When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy. Ulipristal acetate is a selective progesterone receptor modulator with antagonistic and partial agonistic effects (a progesterone agonist/antagonist) at the progesterone receptor.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2bf93d23-cddd-4613-9066-5b5fa090404b. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone